Browse the evidence

Obesity is a chronic, relapsing disease driven by disruptions in homeostatic, hedonic, and cognitive systems, rather than solely a lifestyle outcome, and requires multidisciplinary management including pharmacotherapy and surgery.

Treat obesity as a chronic disease, not a lifestyle failure. For eligible patients, GLP-1 agonists like semaglutide (2.4 mg weekly) combined with lifestyle changes produce significant weight loss (approx. 15%). Manage GI side effects with slow titration. Consider surgery for BMI ≥35.

Osteosarcopenia is defined by the simultaneous loss of muscle mass, muscle strength, bone mass, and functional capacity, and is associated with significantly higher risks of falls, fractures, and mortality compared to having either condition alone.

Osteosarcopenia is the dangerous combination of weak muscles and weak bones. It significantly increases your risk of falls, fractures, and death compared to having just one of these conditions. A comprehensive assessment should check both muscle and bone health.

Obesity is a primary driver of Heart Failure with Preserved Ejection Fraction (HFpEF) through cardiometabolic mechanisms including systemic inflammation, lipotoxicity, and metabolic remodeling, rather than being merely a comorbidity.

If you have HFpEF and obesity, your body's metabolism and inflammation are likely driving your heart condition. This is not just about 'being overweight' but involves complex biological changes like fat toxicity and inflammation. Managing obesity through weight loss interventions (like GLP-1 agonists or lifestyle changes) can target these root causes and improve heart health.

Intensive lifestyle intervention improves cardiovascular risk factors including fitness, HbA1c, systolic blood pressure, and HDL-C levels in individuals with type 2 diabetes, but does not significantly improve LDL-C levels compared to usual care when medication use is accounted for.

While lifestyle changes improve many heart health markers, they may not lower LDL cholesterol as effectively as medications for some individuals. It is important to discuss lipid management with a healthcare provider, as medication might be necessary to achieve LDL goals.

Rapid weight loss via a low-energy diet (810 kcal/day for 8 weeks) induces gender-specific metabolic adaptations: men lose more total body weight and fat mass with greater improvements in metabolic syndrome Z-score, whereas women lose relatively more fat-free mass and experience larger reductions in HDL cholesterol and hip circumference, despite similar improvements in insulin resistance.

If you are using a very low-calorie diet (around 800 kcal/day) to jumpstart weight loss, expect different results based on your sex. Men will likely lose more total weight and fat, with better improvements in overall metabolic risk. Women may lose less total weight but will still improve insulin resistance. However, women should be aware that this specific rapid loss phase may lead to greater loss of lean muscle and a drop in 'good' cholesterol (HDL). This doesn't mean the diet is 'bad' for women, but it highlights the need for careful monitoring and a strong focus on preserving muscle mass (via protein and resistance training) once you transition to a maintenance diet.

High body mass index (BMI) is a causal risk factor for a broad spectrum of chronic diseases, including cardiovascular disease, diabetes, chronic kidney disease, multiple cancers, and musculoskeletal disorders, resulting in significant global mortality and disease burden.

Maintaining a BMI within the 20-25 kg/m2 range is associated with the lowest all-cause mortality risk. This is not just about weight but about reducing the risk of major chronic diseases like heart disease, diabetes, and certain cancers. Public health surveillance and evidence-based interventions are critical to addressing this growing burden.

A significant portion of deaths related to high BMI occur among individuals who are not clinically obese (BMI < 30 kg/m2), indicating that overweight status (BMI 25-29.9) also carries substantial mortality risk.

You do not need to be obese to face increased health risks. Being overweight (BMI 25-29.9) accounts for a large portion of deaths related to high body weight. Aim for a BMI in the 20-25 range to minimize mortality risk.

Higher body-mass index (BMI) is associated with significantly increased mortality rates from all cancers combined and from multiple specific cancer sites, with the highest risks observed in individuals with a BMI of 40 or greater.

Maintaining a BMI in the normal range (18.5-24.9) is one of the most effective ways to reduce your risk of dying from cancer. The risk of cancer death increases steadily as BMI increases, with those having a BMI of 40 or higher facing more than a 50% higher risk of cancer death compared to those of normal weight. This applies to both men and women and covers many specific cancer types.

Overweight and obesity account for a substantial proportion of cancer deaths in the U.S. population, estimated at 14% for men and 20% for women.

Maintaining a healthy weight is a powerful tool for cancer prevention. This study estimates that 14% of cancer deaths in men and 20% in women are attributable to being overweight or obese. By keeping your BMI under 25, you can significantly reduce your risk of dying from cancer.

A targeted, long-term, intensified multifactorial intervention (targeting hyperglycemia, hypertension, dyslipidemia, and microalbuminuria via behavior modification and pharmacotherapy) reduces the risk of cardiovascular and microvascular events by approximately 50% in patients with type 2 diabetes and microalbuminuria compared to conventional treatment.

If you have type 2 diabetes and early kidney warning signs (microalbuminuria), standard care may not be enough to protect your heart and kidneys. This study shows that a rigorous, long-term plan targeting blood sugar, blood pressure, cholesterol, and kidney health simultaneously—supported by frequent check-ins and lifestyle changes—can cut your risk of serious heart and kidney problems by half. It requires commitment to diet, exercise, and medications, but the long-term benefit is substantial.

Obesity (BMI ≥30) significantly increases the risk of developing depression over time, with a pooled odds ratio of 1.55, and this association is stronger in American populations and for clinical diagnoses compared to depressive symptoms.

If you have obesity, be aware that it may increase your risk of developing depression, particularly if you are in a culture with strong thinness ideals (like the US). This risk is mediated by biological factors like inflammation and stress hormones, as well as psychological factors like body dissatisfaction. Treating obesity may help reduce depression risk, and treating depression may help manage weight, suggesting a bidirectional approach to care is beneficial.

Depression (symptoms or disorder) significantly increases the risk of developing obesity (BMI ≥30) over time, with a pooled odds ratio of 1.58, but does not significantly increase the risk of developing overweight (BMI 25-29.99).

If you have depression, be aware that it may increase your risk of developing obesity, especially if your depression is long-standing (≥10 years). This risk is driven by biological factors like stress hormones and lifestyle changes. Treating depression effectively may help prevent obesity, and managing weight may help alleviate depression, suggesting a bidirectional approach to care is beneficial.

Obesity acts as an independent risk factor for cardiovascular disease (CVD) and increases morbidity and mortality through multiple mechanisms, including metabolic alterations, cardiac structural changes, and hemodynamic stress, even in the absence of traditional comorbidities.

Obesity is not just a cosmetic issue or a marker for other diseases; it actively damages the heart's structure and function. Maintaining a healthy weight is one of the most effective ways to reduce your risk of heart disease, heart failure, and stroke, regardless of your cholesterol or blood pressure levels.

Obesity is associated with metabolic syndrome, which significantly increases the risk of cardiovascular disease and mortality, independent of diabetes status.

Metabolic Syndrome is a serious condition that increases your risk of heart disease and death, even if you don't have diabetes. It involves high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. Addressing all these factors is crucial for heart health.

Chronically restricting sleep to 6 hours or less per night for 14 consecutive days produces cumulative cognitive performance deficits equivalent to 1-2 nights of total sleep deprivation, despite subjects remaining largely unaware of their declining performance.

If you consistently sleep 6 hours or less, your cognitive performance (reaction time, memory, decision-making) will degrade daily over two weeks to the level of someone who has been awake for 48 hours. You will not feel this decline because your subjective sense of sleepiness plateaus early. To maintain peak cognitive function, you must prioritize 7-8 hours of sleep, as 'getting used to' less sleep is a dangerous illusion that impairs your performance without your awareness.

Restricting sleep to 4-5 hours per night for seven consecutive nights causes cumulative, escalating deficits in subjective sleepiness, mood disturbance, and psychomotor vigilance performance (specifically increased lapse frequency and duration).

If you restrict your sleep to 4-5 hours a night for a week, your ability to stay alert and perform tasks will get worse every day, even if you don't feel significantly more tired. Your reaction times will slow, and you will make more mistakes (lapses). This is a cumulative effect that builds up over the week.

Bariatric surgery significantly reduces overall mortality, diabetes incidence, and cardiovascular events compared to usual care in obese patients over long-term follow-up.

For individuals with severe obesity (BMI >34-38 depending on sex), bariatric surgery is the most effective intervention for reducing long-term mortality and preventing type 2 diabetes and heart disease compared to lifestyle changes or medication alone. While surgery carries short-term risks, the long-term benefits in survival and disease prevention are substantial and sustained over decades.

Higher levels of total physical activity, regardless of intensity (including light activity), are associated with a substantially reduced risk of all-cause mortality in a non-linear dose-response pattern.

Focus on increasing your total daily movement volume rather than just high-intensity workouts. Aim for at least 10 hours of accelerometer wear time per day for 4+ days to capture accurate data, but practically, this means accumulating light activity (walking, standing) throughout the day. The biggest mortality risk reduction occurs with moderate increases in activity, particularly around 24 minutes of moderate-to-vigorous activity or 375 minutes of light activity per day. Do not neglect light activity; it is highly effective for longevity.

Diagnosing malnutrition requires the concurrent presence of at least one phenotypic criterion (weight loss, low BMI, or reduced muscle mass) and one etiologic criterion (reduced food intake/assimilation or disease burden/inflammation).

To diagnose malnutrition in a clinical setting, you must find evidence of physical changes (like weight loss, low BMI, or muscle loss) AND evidence of a cause (like reduced food intake or active inflammation). Neither alone is sufficient for a diagnosis.

Mood is the most sensitive measure of sleep deprivation, showing greater impairment than cognitive or motor performance, particularly under partial sleep deprivation conditions.

Monitor your mood closely when sleep-deprived. Mood deteriorates more severely than physical or cognitive output, serving as an early warning sign of sleep debt.

Diagnosing malnutrition in adults requires the presence of at least one phenotypic criterion (non-volitional weight loss, low BMI, or reduced muscle mass) AND at least one etiologic criterion (reduced food intake/assimilation or disease burden/inflammation).

To diagnose malnutrition, you cannot rely on just one factor. You must find evidence of physical change (like weight loss, low BMI, or muscle loss) AND evidence of a cause (like poor eating or active inflammation/disease). Both must be present.

Type 2 diabetes incidence in youth is increasing rapidly and is strongly associated with obesity, particularly in minority populations (Native American, African-American, Mexican-American, Japanese).

If you are a parent of a child in a high-risk ethnic group (Native American, African-American, Mexican-American, Japanese) and your child is overweight, discuss Type 2 diabetes screening with their doctor, even if they are young. The risk is real and increasing.

Adherence to a Mediterranean diet supplemented with extra-virgin olive oil (1 L/week) or mixed nuts (30 g/day) slows age-related cognitive decline in older adults at high cardiovascular risk compared to a low-fat control diet.

To support cognitive health as you age, adopt a Mediterranean dietary pattern enriched with specific healthy fats. Specifically, aim for approximately 1 liter of extra-virgin olive oil per week and 30 grams of mixed nuts (walnuts, hazelnuts, almonds) daily. This approach has been shown in a major clinical trial to slow cognitive decline in older adults at high cardiovascular risk, outperforming standard low-fat dietary advice.

High body mass index (BMI ≥ 25 kg/m²) is a major global cause of disease burden, contributing to 2.4 million deaths and 70.7 million disability-adjusted life years (DALYs) in females and 2.3 million deaths and 77.0 million DALYs in males in 2017, with cardiovascular disease, diabetes, and kidney diseases being the leading causes.

Maintaining a BMI within the healthy range (typically 18.5–24.9 kg/m²) is critical for preventing cardiovascular disease, diabetes, and kidney disease. Public health initiatives should target population-wide strategies to reduce high BMI, tailored to the development status of specific regions.